Small molecule degraders such as PROTACs (PROteolysis TArgeting Chimeras) have
emerged as new promising pharmacological modalities and the first PROTAC drug …

The RAS-ERK pathway is a fundamental signaling cascade crucial for many biological
processes including proliferation, cell cycle control, growth, and survival; common across all …

Designing binders to target undruggable proteins presents a formidable challenge in drug
discovery. In this work, we provide an algorithmic framework to design short, target-binding …

Protein-protein interactions (PPIs) are critical for biological processes and predicting the
sites of these interactions is useful for both computational and experimental applications. We …

Designing binders to target undruggable proteins presents a formidable challenge in drug
discovery, requiring innovative approaches to overcome the lack of putative binding sites …

Highlights•Targeted-protein degradation supports fundamental discovery and drug
development.•Biologics-based degraders target intracellular, extracellular, and membrane …

Proteins can be targeted for degradation by engineering biomolecules that direct them to the
eukaryotic ubiquitination machinery. For instance, the fusion of an E3 ubiquitin ligase to a …

Protein turnover, a highly regulated process governed by the ubiquitin–proteasome system
(UPS), is essential for maintaining cellular homeostasis. Dysregulation of the UPS has been …

Protein biologics are powerful therapeutic agents with diverse inhibitory and enzymatic
functions. However, their clinical use has been limited to extracellular applications due to …

Abstract The concept of Targeted Protein Degradation (TPD) has been introduced as an
attractive alternative to the development of classical inhibitors. TPD can extend the range of …